HE Jin
The First Affiliated Hospital,WANG Yan
The First Affiliated Hospital, ;Institute of Cardiovascular Diseases, University of South China, Hengyang, Hunan 421001, ChinaMENG Jun
The First Affiliated Hospital,ZENG Zhaolin
Institute of Cardiovascular Diseases, University of South China, Hengyang, Hunan 421001, ChinaCHEN Jiaojiao
Institute of Cardiovascular Diseases, University of South China, Hengyang, Hunan 421001, ChinaLIU Yami
The First Affiliated Hospital, ;Institute of Cardiovascular Diseases, University of South China, Hengyang, Hunan 421001, ChinaTAO Jun
Institute of Cardiovascular Diseases, University of South China, Hengyang, Hunan 421001, ChinaGUI Peigen
The First Affiliated Hospital,WANG Zuo
Institute of Cardiovascular Diseases, University of South China, Hengyang, Hunan 421001, China(1.The First Affiliated Hospital, ;2.Institute of Cardiovascular Diseases, University of South China, Hengyang, Hunan 421001, China)
R34
HE Jin, WANG Yan, MENG Jun, ZENG Zhaolin, CHEN Jiaojiao, LIU Yami, TAO Jun, GUI Peigen, WANG Zuo. MEG3 inhibits apolipoprotein(a) expression in HepG2 cells through the miR-125a-5p/TET2 pathway[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2018,26(9):888-894.
Copy